Share this Page:
In this randomised phase 3 trial, the effectiveness and safety of adjuvant nivolumab plus ipilimumab was assessed. The combination of nivolumab plus ipilimumab was given for 6 months after surgery (nephrectomy or partial nephrectomy) and compared with placebo in patients with localised kidney cancer that was at high risk of coming back.
Disease-free survival was similar for patients on nivolumab plus ipilimumab compared to placebo.
These study findings do not support the use of adjuvant nivolumab plus ipilimumab in patients with kidney cancer at high risk of returning after surgery.